Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Johnson and Johnson
Daiichi Sankyo
US Army
Boehringer Ingelheim
Argus Health
Harvard Business School

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,803,081

« Back to Dashboard

Summary for Patent: 4,803,081

Title: New pharmaceutical preparations with extended release
Abstract:An extended release perparation of an active compound with very low solubility containing the active compound dissolved or dispersed in a semi-solid or liquid non-ionic solubilizer and whereby the amount by weight of the solubilizer is at least equal to the amount by weight of the active compound as well as a process for the preparation thereof.
Inventor(s): Falk; Karl-Erik L. (Lindome, SE), Hugosson; Sven M. (Kungsbacka, SE), Rosinski; Adam (Molndal, SE), Sjogren; John A. (Molnlycke, SE)
Assignee: Aktiebolaget Hassle (Molndal, SE)
Application Number:07/034,500
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,803,081

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden8601624Apr 11, 1986

International Patent Family for Patent: 4,803,081

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany3779183► Subscribe
Spain2031929► Subscribe
European Patent Office0249587► Subscribe
Egypt18265► Subscribe
Algeria1067► Subscribe
Denmark173033► Subscribe
Denmark154987► Subscribe
Finland871585► Subscribe
Finland91826► Subscribe
Greece3005286► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus